SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the American Society of Hematology’s 49th Annual Meeting
DUBLIN, Calif., Dec. 3 /PRNewswire-FirstCall/ — SuperGen Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for presentation at the American Society of Hematology’s 49th Annual Meeting from Dec. 8-11 at the Georgia World Congress Center in Atlanta.
The poster presentations will focus on data regarding two of SuperGen’s current oncology programs that target PIM and JAK2 kinases in hematological malignancies, respectively.
The oral presentation will focus on data from the induction of fetal hemoglobin in baboons using a novel hypomethylating agent, S110, to ameliorate symptoms associated with sickle cell anemia.
SuperGen’s schedule of presentations is as follows: Date Time (EDT) and Abstract # and Title Poster Number Location Sunday, 9:00 a.m. – 8:00 p.m. #2655 – Targeting PIM 845 Dec. 9 5:30 p.m. – 7:30 p.m. Kinases in Hematological Hall B3 & B4 Malignancies Monday, 10:30 a.m. – 7:00 p.m. #3560 – Targeting the JAK2 779 Dec. 10 5:00 p.m. – 7:00 p.m. Kinase in Hematological Hall B3 & B4 Malignancies Monday, Oral Presentation #571 – Fetal Hemoglobin N/A Dec. 10 1:30 p.m. – 3:00 p.m. Induction in Baboons (P. Anubis) Following Rooms B216 – B217 Administration of a Novel Decitabine Dinucleotide (S110) Compound About SuperGen
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com/.
Forward-Looking Statements
This news release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,”"expects,”"anticipates,”"intends,”"will,”"may,”"should,” or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company’s results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company’s filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
Contacts Timothy L. Enns Mary M. Vegh SuperGen, Inc. SuperGen, Inc. SVP, Corporate Communications & Business Manager, Investor Development Relations Tel: (925) 560-0100 Tel: (925) 560-2845 E-mail: tenns@supergen.com E-mail: mary.vegh@supergen.com
SuperGen Inc.
CONTACT: Timothy L. Enns, SVP, Corporate Communications & Business,+1-925-560-0100, tenns@supergen.com; or Mary M. Vegh, Manager, InvestorRelations, +1-925-560-2845, mary.vegh@supergen.com, both of SuperGen Inc.
Web site: http://www.supergen.com/